Cambridge University biotech spin-out Definigen has secured £1.3m ($2.13m) in series A funding in a round led by the university’s tech transfer unit Cambridge Enterprise, and joined by early-stage investor 24Haymarket and Cambridge-based biotech Abcam’s co-founder Jonathan Milner.
Cambridge Enterprise’s involvement marks the largest investment made by the university through its seed funds in a single round to date, weighing in at £525,000.
Founded in April last year, Definigen is commercialising stem cell technology developed at Cambridge, and is one of the first commercial enterprises to come out from the university’s research into stem cells. Specifically, the company supplies human liver cells for drug development and disease modelling applications.
The latest funding will be used to accelerate production of the liver cells as well as introducing new products to market.
